SO
INZY

STRS Ohio’s Inozyme Pharma INZY Stock Holding History

STRS Ohio’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-9,900
Closed -$41K – 1960
2023
Q3 		$41K Buy
+9,900
New +$50.4K ﹤0.01% 1814
2021
Q2 		– Sell
-2,000
Closed -$39K – 2324
2021
Q1 		$39K Hold
2,000
– – ﹤0.01% 2060
2020
Q4 		$41K Hold
2,000
– – ﹤0.01% 2015
2020
Q3 		$52K Buy
+2,000
New +$49.7K ﹤0.01% 1964

Other funds holding INZY

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

STRS Ohio's INZY Position: Q4 2023 in Review

STRS Ohio sold out of Inozyme Pharma (INZY) in Q4 2023, closing a stake of 9,900 shares — an estimated $41K sold.

STRS Ohio first reported a position in INZY in Q3 2020 and held it in 4 quarters. The position peaked at $52K in Q3 2020. 80 funds tracked by Wall St. Rank hold INZY as of Q4 2023.

  • STRS Ohio reported no remaining Inozyme Pharma position as of Q4 2023 after selling out during the quarter.
  • STRS Ohio sold 9,900 Inozyme Pharma shares in Q4 2023, an estimated $41K.
  • STRS Ohio first reported a position in Inozyme Pharma in Q3 2020 and held it in 4 quarters.
  • STRS Ohio's Inozyme Pharma position peaked at $52K in Q3 2020.
  • 80 funds tracked by Wall St. Rank held Inozyme Pharma as of Q4 2023.

Based on STRS Ohio's 13F filing for Q4 2023, filed 30 Jan 2024.